Chung Yih-Lin, Sheu Meei-Ling, Yang Shun-Chun, Lin Chi-Hung, Yen Sang-Hue
Department of Radiation Oncology, Koo Foundation Sun Yat-Sen Cancer Center, No. 125 Lih-Der Road, Pei-Tou District, Taipei 112, Taiwan, Republic of China.
Int J Cancer. 2002 Jan 20;97(3):306-12. doi: 10.1002/ijc.1614.
Overexpression of Her2/neu is implicated in the development of resistance to the antiestrogen tamoxifen (TAM) that exerts its inhibitory effect through interaction with estrogen receptor (ER). Whereas Her2/neu and ER are believed to be important cell survival/death factors in human breast cancer cells, if and how they interact to confer resistance to hormone therapy is not known. This prompted us to investigate whether modulation of the effect of TAM occurs via the Her2/neu pathway and whether targeting the interaction between the Her2/neu pathway and the ER pathway is beneficial. There are 2 forms of ER that are localized to the cell membrane and to the nucleus. For the first time, we found that Her2/neu directly interacts with ER at the cell membrane. We then investigated the role of Her2/neu overexpression in the regulation of the cell membrane ER pathway in TAM-resistant breast cancer cells and the nature of this interaction in apoptotic signaling. Relief of TAM resistance was associated with Her2/neu downregulation and ER upregulation. TAM-induced apoptosis occurred immediately after dissociation of Her2/neu from cell membrane ER. These results demonstrate a novel mechanism by which Her2/neu regulates the cell membrane ER-coupled apoptosis and the possible involvement of the Her2/neu in TAM resistance of breast cancer cells. Moreover, the antiproliferative activity of TAM should rely on the integration between the signal transduction from the cell membrane ER and the gene regulation by the nuclear ER. Coordinated modulation on the cell membrane ER/Her2/neu pathway and the nuclear ER/RAR pathway may provide a new approach for treatment of ER-positive, Her2/neu overexpressing breast cancer.
Her2/neu的过表达与抗雌激素他莫昔芬(TAM)耐药性的产生有关,TAM通过与雌激素受体(ER)相互作用发挥其抑制作用。虽然Her2/neu和ER被认为是人类乳腺癌细胞中重要的细胞存活/死亡因子,但它们是否以及如何相互作用以赋予激素治疗耐药性尚不清楚。这促使我们研究TAM的作用调节是否通过Her2/neu途径发生,以及靶向Her2/neu途径与ER途径之间的相互作用是否有益。ER有两种形式,分别定位于细胞膜和细胞核。我们首次发现Her2/neu在细胞膜上直接与ER相互作用。然后我们研究了Her2/neu过表达在耐TAM乳腺癌细胞膜ER途径调节中的作用以及这种相互作用在凋亡信号传导中的性质。TAM耐药性的缓解与Her2/neu下调和ER上调有关。TAM诱导的凋亡在Her2/neu从细胞膜ER解离后立即发生。这些结果证明了一种新的机制,即Her2/neu调节细胞膜ER偶联的凋亡以及Her2/neu可能参与乳腺癌细胞的TAM耐药性。此外,TAM的抗增殖活性应依赖于细胞膜ER的信号转导与核ER的基因调控之间的整合。对细胞膜ER/Her2/neu途径和核ER/RAR途径的协同调节可能为治疗ER阳性、Her2/neu过表达的乳腺癌提供一种新方法。